Patent(s) and the Corresponding Patented Drug(s) |
Top |
United States Patent and Trademark Office (USPTO) |
Patent ID |
US9708269 |
Title |
Process for making isoquinoline compounds |
Abstract |
The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby. Such compounds can be used to prepare compounds and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). |
Applicant(s) |
FibroGen, Inc. |
Representative Drug(s) |
D0LO2C |
Drug Info
|
IC50 = 2200 nM |
Click to Show More |
[1] |
2
|
D0V6AZ
|
Drug Info
|
IC50 = 2200 nM
|
[1] |
3
|
D0D8AV
|
Drug Info
|
IC50 = 3500 nM
|
[1] |
Patent ID |
US9708269 |
Title |
Process for making isoquinoline compounds |
Abstract |
The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby. Such compounds can be used to prepare compounds and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). |
Applicant(s) |
FibroGen, Inc. |
Representative Drug(s) |
D0LO2C |
Drug Info
|
IC50 = 2200 nM |
Click to Show More |
[1] |
2
|
D0V6AZ
|
Drug Info
|
IC50 = 2200 nM
|
[1] |
3
|
D0D8AV
|
Drug Info
|
IC50 = 3500 nM
|
[1] |
Patent ID |
US9708269 |
Title |
Process for making isoquinoline compounds |
Abstract |
The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby. Such compounds can be used to prepare compounds and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). |
Applicant(s) |
FibroGen, Inc. |
Representative Drug(s) |
D0LO2C |
Drug Info
|
IC50 = 2200 nM |
Click to Show More |
[1] |
2
|
D0V6AZ
|
Drug Info
|
IC50 = 2200 nM
|
[1] |
3
|
D0D8AV
|
Drug Info
|
IC50 = 3500 nM
|
[1] |
Patent ID |
US9695170 |
Title |
Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase |
Abstract |
The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). |
Applicant(s) |
FibroGen, Inc. |
Representative Drug(s) |
D04YMG |
Drug Info
|
IC50 = 630 nM |
Click to Show More |
[2] |
2
|
D0YY5J
|
Drug Info
|
IC50 = 2100 nM
|
[2] |
3
|
D02IRO
|
Drug Info
|
IC50 = 12000 nM
|
[2] |
Patent ID |
US9695170 |
Title |
Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase |
Abstract |
The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). |
Applicant(s) |
FibroGen, Inc. |
Representative Drug(s) |
D04YMG |
Drug Info
|
IC50 = 630 nM |
Click to Show More |
[2] |
2
|
D0YY5J
|
Drug Info
|
IC50 = 2100 nM
|
[2] |
3
|
D02IRO
|
Drug Info
|
IC50 = 12000 nM
|
[2] |
Patent ID |
US9695170 |
Title |
Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase |
Abstract |
The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). |
Applicant(s) |
FibroGen, Inc. |
Representative Drug(s) |
D04YMG |
Drug Info
|
IC50 = 630 nM |
Click to Show More |
[2] |
2
|
D0YY5J
|
Drug Info
|
IC50 = 2100 nM
|
[2] |
3
|
D02IRO
|
Drug Info
|
IC50 = 12000 nM
|
[2] |
Patent ID |
US9598370 |
Title |
Prolyl hydroxylase inhibitors and methods of use |
Abstract |
The present disclosure relates to HIF-1 prolyl hydroxylase inhibitors, compositions which comprise the HIF-1 prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. |
Applicant(s) |
Akebia Therapeutics, Inc. |
Representative Drug(s) |
D00ECX |
Drug Info
|
IC50 = 3700 nM |
[3] |
Patent ID |
US9422240 |
Title |
Partially saturated nitrogen-containing heterocyclic compound |
Abstract |
There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I): (in the above-mentioned general formula (I),W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof. |
Applicant(s) |
TAISHO PHARMACEUTICAL CO., LTD |
Representative Drug(s) |
D0L9XU |
Drug Info
|
IC50 = 61 nM |
Click to Show More |
[4] |
2
|
D05EHX
|
Drug Info
|
IC50 = 77 nM
|
[4] |
3
|
D00CAO
|
Drug Info
|
IC50 = 79 nM
|
[4] |
4
|
D0K5UR
|
Drug Info
|
IC50 = 89 nM
|
[4] |
Patent ID |
US9422240 |
Title |
Partially saturated nitrogen-containing heterocyclic compound |
Abstract |
There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I): (in the above-mentioned general formula (I),W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof. |
Applicant(s) |
TAISHO PHARMACEUTICAL CO., LTD |
Representative Drug(s) |
D0L9XU |
Drug Info
|
IC50 = 61 nM |
Click to Show More |
[4] |
2
|
D05EHX
|
Drug Info
|
IC50 = 77 nM
|
[4] |
3
|
D00CAO
|
Drug Info
|
IC50 = 79 nM
|
[4] |
4
|
D0K5UR
|
Drug Info
|
IC50 = 89 nM
|
[4] |
Patent ID |
US9422240 |
Title |
Partially saturated nitrogen-containing heterocyclic compound |
Abstract |
There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I): (in the above-mentioned general formula (I),W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof. |
Applicant(s) |
TAISHO PHARMACEUTICAL CO., LTD |
Representative Drug(s) |
D0L9XU |
Drug Info
|
IC50 = 61 nM |
Click to Show More |
[4] |
2
|
D05EHX
|
Drug Info
|
IC50 = 77 nM
|
[4] |
3
|
D00CAO
|
Drug Info
|
IC50 = 79 nM
|
[4] |
4
|
D0K5UR
|
Drug Info
|
IC50 = 89 nM
|
[4] |
Patent ID |
US9422240 |
Title |
Partially saturated nitrogen-containing heterocyclic compound |
Abstract |
There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I): (in the above-mentioned general formula (I),W, Y, R2, R3, R4, and Y4 are as described hereinabove), or pharmaceutically acceptable salts thereof. |
Applicant(s) |
TAISHO PHARMACEUTICAL CO., LTD |
Representative Drug(s) |
D0L9XU |
Drug Info
|
IC50 = 61 nM |
Click to Show More |
[4] |
2
|
D05EHX
|
Drug Info
|
IC50 = 77 nM
|
[4] |
3
|
D00CAO
|
Drug Info
|
IC50 = 79 nM
|
[4] |
4
|
D0K5UR
|
Drug Info
|
IC50 = 89 nM
|
[4] |
Patent ID |
US9409892 |
Title |
4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors |
Abstract |
The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias. |
Applicant(s) |
FibroGen, Inc. |
Representative Drug(s) |
D0R4CX |
Drug Info
|
IC50 = 860 nM |
Click to Show More |
[5] |
2
|
D0V9WU
|
Drug Info
|
IC50 = 22830 nM
|
[5] |
3
|
D0SM8Z
|
Drug Info
|
IC50 = 24480 nM
|
[5] |
4
|
D0VK5C
|
Drug Info
|
IC50 = 200000 nM
|
[5] |
Patent ID |
US9409892 |
Title |
4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors |
Abstract |
The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias. |
Applicant(s) |
FibroGen, Inc. |
Representative Drug(s) |
D0R4CX |
Drug Info
|
IC50 = 860 nM |
Click to Show More |
[5] |
2
|
D0V9WU
|
Drug Info
|
IC50 = 22830 nM
|
[5] |
3
|
D0SM8Z
|
Drug Info
|
IC50 = 24480 nM
|
[5] |
4
|
D0VK5C
|
Drug Info
|
IC50 = 200000 nM
|
[5] |
Patent ID |
US9409892 |
Title |
4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors |
Abstract |
The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias. |
Applicant(s) |
FibroGen, Inc. |
Representative Drug(s) |
D0R4CX |
Drug Info
|
IC50 = 860 nM |
Click to Show More |
[5] |
2
|
D0V9WU
|
Drug Info
|
IC50 = 22830 nM
|
[5] |
3
|
D0SM8Z
|
Drug Info
|
IC50 = 24480 nM
|
[5] |
4
|
D0VK5C
|
Drug Info
|
IC50 = 200000 nM
|
[5] |
Patent ID |
US9409892 |
Title |
4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors |
Abstract |
The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias. |
Applicant(s) |
FibroGen, Inc. |
Representative Drug(s) |
D0R4CX |
Drug Info
|
IC50 = 860 nM |
Click to Show More |
[5] |
2
|
D0V9WU
|
Drug Info
|
IC50 = 22830 nM
|
[5] |
3
|
D0SM8Z
|
Drug Info
|
IC50 = 24480 nM
|
[5] |
4
|
D0VK5C
|
Drug Info
|
IC50 = 200000 nM
|
[5] |
Patent ID |
US9340511 |
Title |
Process for making isoquinoline compounds |
Abstract |
The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby. Such compounds can be used to prepare compounds and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). |
Applicant(s) |
FibroGen, Inc. |
Representative Drug(s) |
D0MS5W |
Drug Info
|
IC50 = 5200 nM |
[6] |
Patent ID |
US9115085 |
Title |
Crystalline forms of a prolyl hydroxylase inhibitor |
Abstract |
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof. |
Applicant(s) |
FIBROGEN, INC. |
Patent ID |
US8921389 |
Title |
Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase |
Abstract |
The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). |
Applicant(s) |
Fibrogen, Inc. |
Representative Drug(s) |
D0I4PX |
Drug Info
|
IC50 = 10000 nM |
Click to Show More |
[8] |
2
|
D0Y3NI
|
Drug Info
|
IC50 = 16000 nM
|
[8] |
Patent ID |
US8921389 |
Title |
Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase |
Abstract |
The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). |
Applicant(s) |
Fibrogen, Inc. |
Representative Drug(s) |
D0I4PX |
Drug Info
|
IC50 = 10000 nM |
Click to Show More |
[8] |
2
|
D0Y3NI
|
Drug Info
|
IC50 = 16000 nM
|
[8] |
Patent ID |
US8778412 |
Title |
Methods for increasing the stabilization of hypoxia inducible factor-1 alpha |
Abstract |
Disclosed herein are methods for controlling the activity of hypoxia-inducible transcription factor 1-alpha (HIF-1) and diseases, conditions, or syndromes related thereto, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. Further disclosed are pharmaceutical compositions comprising HIF-1 prolyl hydroxylase inhibitors useful in treating diseases, conditions, and/or syndromes related thereto the activity of HIF-1. |
Applicant(s) |
Aerpio Therapeutics Inc. |
Representative Drug(s) |
D01PPR |
Drug Info
|
IC50 = 11000 nM |
[9] |
Patent ID |
US8722895 |
Title |
Prolyl hydroxylase inhibitors and method of use |
Abstract |
The present disclosure relates to HIF-1 prolyl hydroxylase inhibitors, compositions which comprise the HIF-1 prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. |
Applicant(s) |
Akebia Therapeutics, Inc. |
Representative Drug(s) |
D00XHH |
Drug Info
|
IC50 = 3700 nM |
[10] |
Patent ID |
US8598210 |
Title |
Prolyl hydroxylase inhibitors and methods of use |
Abstract |
The present disclosure relates to HIF-1 prolyl hydroxylase inhibitors, compositions which comprise the HIF-1 prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. |
Applicant(s) |
Akebia Therapeutics, Inc. |
Representative Drug(s) |
D01XZT |
Drug Info
|
IC50 = 650 nM |
Click to Show More |
[11] |
2
|
D0Q9AF
|
Drug Info
|
IC50 = 2800 nM
|
[11] |
Patent ID |
US8598210 |
Title |
Prolyl hydroxylase inhibitors and methods of use |
Abstract |
The present disclosure relates to HIF-1 prolyl hydroxylase inhibitors, compositions which comprise the HIF-1 prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. |
Applicant(s) |
Akebia Therapeutics, Inc. |
Representative Drug(s) |
D01XZT |
Drug Info
|
IC50 = 650 nM |
Click to Show More |
[11] |
2
|
D0Q9AF
|
Drug Info
|
IC50 = 2800 nM
|
[11] |
Patent ID |
US8536181 |
Title |
Prolyl hydroxylase inhibitors |
Abstract |
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response. |
Applicant(s) |
Aerpio Therapeutics Inc. |
Representative Drug(s) |
D0HN5O |
Drug Info
|
IC50 = 12000 nM |
Click to Show More |
[12] |
2
|
D03PGC
|
Drug Info
|
IC50 = 12000 nM
|
[12] |
3
|
D00IKR
|
Drug Info
|
IC50 = 14000 nM
|
[12] |
Patent ID |
US8536181 |
Title |
Prolyl hydroxylase inhibitors |
Abstract |
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response. |
Applicant(s) |
Aerpio Therapeutics Inc. |
Representative Drug(s) |
D0HN5O |
Drug Info
|
IC50 = 12000 nM |
Click to Show More |
[12] |
2
|
D03PGC
|
Drug Info
|
IC50 = 12000 nM
|
[12] |
3
|
D00IKR
|
Drug Info
|
IC50 = 14000 nM
|
[12] |
Patent ID |
US8536181 |
Title |
Prolyl hydroxylase inhibitors |
Abstract |
Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response. |
Applicant(s) |
Aerpio Therapeutics Inc. |
Representative Drug(s) |
D0HN5O |
Drug Info
|
IC50 = 12000 nM |
Click to Show More |
[12] |
2
|
D03PGC
|
Drug Info
|
IC50 = 12000 nM
|
[12] |
3
|
D00IKR
|
Drug Info
|
IC50 = 14000 nM
|
[12] |
Patent ID |
US10149841 |
Title |
Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof |
Abstract |
A compound of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently H; R3 is selected from H, a C1-C7 straight-chain, and a branched or cyclic alkyl; and R4, R5, R6, R7, and R8 are each independently selected from C1-C7 alkyl, halo C1-C7 alkyl and the like. Also provided is a method for preparing the compound, pharmaceutical compositions including the compound or pharmaceutically acceptable salts thereof, and uses of the compound or pharmaceutically acceptable salt thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO. |
Applicant(s) |
SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. |
Representative Drug(s) |
D0QI0J |
Drug Info
|
IC50 = 15000 nM |
Click to Show More |
[13] |
2
|
D0F0DX
|
Drug Info
|
IC50 = 63000 nM
|
[13] |
3
|
D0JR2Q
|
Drug Info
|
IC50 = 84000 nM
|
[13] |
4
|
D0OR4X
|
Drug Info
|
IC50 = 237000 nM
|
[13] |
Patent ID |
US10149841 |
Title |
Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof |
Abstract |
A compound of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently H; R3 is selected from H, a C1-C7 straight-chain, and a branched or cyclic alkyl; and R4, R5, R6, R7, and R8 are each independently selected from C1-C7 alkyl, halo C1-C7 alkyl and the like. Also provided is a method for preparing the compound, pharmaceutical compositions including the compound or pharmaceutically acceptable salts thereof, and uses of the compound or pharmaceutically acceptable salt thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO. |
Applicant(s) |
SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. |
Representative Drug(s) |
D0QI0J |
Drug Info
|
IC50 = 15000 nM |
Click to Show More |
[13] |
2
|
D0F0DX
|
Drug Info
|
IC50 = 63000 nM
|
[13] |
3
|
D0JR2Q
|
Drug Info
|
IC50 = 84000 nM
|
[13] |
4
|
D0OR4X
|
Drug Info
|
IC50 = 237000 nM
|
[13] |
Patent ID |
US10149841 |
Title |
Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof |
Abstract |
A compound of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently H; R3 is selected from H, a C1-C7 straight-chain, and a branched or cyclic alkyl; and R4, R5, R6, R7, and R8 are each independently selected from C1-C7 alkyl, halo C1-C7 alkyl and the like. Also provided is a method for preparing the compound, pharmaceutical compositions including the compound or pharmaceutically acceptable salts thereof, and uses of the compound or pharmaceutically acceptable salt thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO. |
Applicant(s) |
SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. |
Representative Drug(s) |
D0QI0J |
Drug Info
|
IC50 = 15000 nM |
Click to Show More |
[13] |
2
|
D0F0DX
|
Drug Info
|
IC50 = 63000 nM
|
[13] |
3
|
D0JR2Q
|
Drug Info
|
IC50 = 84000 nM
|
[13] |
4
|
D0OR4X
|
Drug Info
|
IC50 = 237000 nM
|
[13] |
Patent ID |
US10149841 |
Title |
Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof |
Abstract |
A compound of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently H; R3 is selected from H, a C1-C7 straight-chain, and a branched or cyclic alkyl; and R4, R5, R6, R7, and R8 are each independently selected from C1-C7 alkyl, halo C1-C7 alkyl and the like. Also provided is a method for preparing the compound, pharmaceutical compositions including the compound or pharmaceutically acceptable salts thereof, and uses of the compound or pharmaceutically acceptable salt thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO. |
Applicant(s) |
SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. |
Representative Drug(s) |
D0QI0J |
Drug Info
|
IC50 = 15000 nM |
Click to Show More |
[13] |
2
|
D0F0DX
|
Drug Info
|
IC50 = 63000 nM
|
[13] |
3
|
D0JR2Q
|
Drug Info
|
IC50 = 84000 nM
|
[13] |
4
|
D0OR4X
|
Drug Info
|
IC50 = 237000 nM
|
[13] |
Patent ID |
US10100051 |
Title |
Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof |
Abstract |
A compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, a preparation method thereof and a pharmaceutical use thereof are provided. In particular, the compound has the following Formula (I), wherein R2 and R3 are each independently H; R1 is H or C1-C3 alkyl; Ar is an aromatic ring or a heteroaromatic ring selected from a naphthalene ring, a pyridine ring, a thiophene ring, a furan ring and a substituted benzene ring. Pharmaceutically acceptable salts of the present compound, are provided, as well as uses of the compound or pharmaceutically acceptable salts thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO. |
Applicant(s) |
SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. |
Representative Drug(s) |
D05TTX |
Drug Info
|
IC50 = 330 nM |
Click to Show More |
[14] |
2
|
D0VI2M
|
Drug Info
|
IC50 = 510 nM
|
[14] |
3
|
D05FDR
|
Drug Info
|
IC50 = 33000 nM
|
[14] |
4
|
D04BTN
|
Drug Info
|
IC50 = 73000 nM
|
[14] |
Patent ID |
US10100051 |
Title |
Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof |
Abstract |
A compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, a preparation method thereof and a pharmaceutical use thereof are provided. In particular, the compound has the following Formula (I), wherein R2 and R3 are each independently H; R1 is H or C1-C3 alkyl; Ar is an aromatic ring or a heteroaromatic ring selected from a naphthalene ring, a pyridine ring, a thiophene ring, a furan ring and a substituted benzene ring. Pharmaceutically acceptable salts of the present compound, are provided, as well as uses of the compound or pharmaceutically acceptable salts thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO. |
Applicant(s) |
SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. |
Representative Drug(s) |
D05TTX |
Drug Info
|
IC50 = 330 nM |
Click to Show More |
[14] |
2
|
D0VI2M
|
Drug Info
|
IC50 = 510 nM
|
[14] |
3
|
D05FDR
|
Drug Info
|
IC50 = 33000 nM
|
[14] |
4
|
D04BTN
|
Drug Info
|
IC50 = 73000 nM
|
[14] |
Patent ID |
US10100051 |
Title |
Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof |
Abstract |
A compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, a preparation method thereof and a pharmaceutical use thereof are provided. In particular, the compound has the following Formula (I), wherein R2 and R3 are each independently H; R1 is H or C1-C3 alkyl; Ar is an aromatic ring or a heteroaromatic ring selected from a naphthalene ring, a pyridine ring, a thiophene ring, a furan ring and a substituted benzene ring. Pharmaceutically acceptable salts of the present compound, are provided, as well as uses of the compound or pharmaceutically acceptable salts thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO. |
Applicant(s) |
SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. |
Representative Drug(s) |
D05TTX |
Drug Info
|
IC50 = 330 nM |
Click to Show More |
[14] |
2
|
D0VI2M
|
Drug Info
|
IC50 = 510 nM
|
[14] |
3
|
D05FDR
|
Drug Info
|
IC50 = 33000 nM
|
[14] |
4
|
D04BTN
|
Drug Info
|
IC50 = 73000 nM
|
[14] |
Patent ID |
US10100051 |
Title |
Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof |
Abstract |
A compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, a preparation method thereof and a pharmaceutical use thereof are provided. In particular, the compound has the following Formula (I), wherein R2 and R3 are each independently H; R1 is H or C1-C3 alkyl; Ar is an aromatic ring or a heteroaromatic ring selected from a naphthalene ring, a pyridine ring, a thiophene ring, a furan ring and a substituted benzene ring. Pharmaceutically acceptable salts of the present compound, are provided, as well as uses of the compound or pharmaceutically acceptable salts thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO. |
Applicant(s) |
SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. |
Representative Drug(s) |
D05TTX |
Drug Info
|
IC50 = 330 nM |
Click to Show More |
[14] |
2
|
D0VI2M
|
Drug Info
|
IC50 = 510 nM
|
[14] |
3
|
D05FDR
|
Drug Info
|
IC50 = 33000 nM
|
[14] |
4
|
D04BTN
|
Drug Info
|
IC50 = 73000 nM
|
[14] |